- Home
- » Tags
- » Eptinezumab
Top View
- Medical Drug Benefit Clinical Criteriaupdates
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- (INN) for Biological and Biotechnological Substances
- PDL)/Non-Preferred Drug List (NPDL
- Masshealth Partial Unified Formulary (PUF) Note: Information May Have Changed
- Agents for Migraine – Nurtec ODT (Rimegepant), Ubrelvy (Ubrogepant) P&T Approval Date 10/2020; 2/2021 Effective Date 4/1/2021; Oxford: 5/1/2021
- Erenumab for the Prevention of Migraine, Including the Rationale, Findings and Clinical Implications of the LIBERTY Study
- American Headache Society 61St Annual Scientific Meeting POSTER PRESENTATIONS Friday, July 12 and Saturday, July 13, 2019
- Vyepti™ (Eptinezumab-Jjmr) Page 1 of 6 Unitedhealthcare Commercial Medical Benefit Drug Policy Effective 02/01/2021 Proprietary Information of Unitedhealthcare
- Blue Rx Value Plus Formulary
- Calcitonin Gene-Related Peptide (CGRP) Antagonist C15443-C
- CGRP Antagonists for the Treatment of Chronic Migraines: Acomprehensivereview
- Nurtec ODT (Rimegepant) Quantity Override
- FEP 5 Tier Rx Drug Formulary (607) Standard Option
- Therapeutic Drug Class
- Lääkeaineiden Yleisnimet (INN-Nimet) 31.12.2019
- Pharmacologic Characterization of ALD403, a Potent Neutralizing Humanized Monoclonal Antibody Against the Calcitonin Gene- Related Peptide
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled
- Vyepti® (Eptinezumab-Jjmr) (Intravenous) Document Number: IC-0527 Last Review Date: 10/01/2020 Date of Origin: 04/01/2020 Dates Reviewed: 04/2020, 10/2020
- Health Plan Insights
- Monoclonal Antibodies Targeting CGRP: from Clinical Studies to Real-World Evidence—What Do We Know So Far?
- Calcitonin Gene Related Peptide (CGRP) Inhibitors
- Migraine Care in the Era of COVID‐19: Clinical Pearls and Plea To
- Blocking CGRP in Migraine Patients – a Review of Pros and Cons
- DUR) Board Meeting
- Anti‐Migraine Calcitonin Gene–Related Peptide Receptor
- Migraine Treatment
- A Meta-Analysis from Randomized Controlled Trials
- Emerging Drugs for Migraine Treatment: an Update
- Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases
- The Trevena Team Continues to Be Guided by an Unwavering Comm
- CGRP) Inhibitors for Preventative and Acute Migraine Treatment for the Outcomes of Headache Frequency, Reduction in the Number of Migraines, and Quality of Life? 2
- FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
- Prior Authorization — Premium
- Effects of Monoclonal Antagonist Antibodies on Calcitonin Gene-Related Peptide Receptor Function and Trafficking
- Eptinezumab-Jjmr)
- Abstract Book
- Migraine Immunotherapy
- Biological Product Deviation Reporting and HCT/P Deviation Reporting – Non-Blood Product Codes
- CDER Therapeutic Biologic Products
- LATEST NEWS FDA Updates Relating to Biosimilars
- Policy/ Coverage Criteria Guideline Revision Summary Description
- Corporate Medical Policy Eptinezumab-Jjmr (Vyepti™) “Notification”
- CGRP and Headache
- Calcitonin Gene-Related Peptide (Receptor) Antibodies: an Exciting Avenue for Migraine Treatment Antoinette Maassenvandenbrink1, Gisela M
- 212728Orig1s000 SUMMARY REVIEW
- The Market for Migraine Drugs
- Can Monoclonal Antibodies Against CGRP Offer New Treatment Options for Type 2 Diabetes?
- Rimegepant (Nurtec) Criteria for Use March 2021
- (CMS) Healthcare Common Procedure Coding System (HCPCS) Application Summaries and Coding Decisions
- Anti-CGRP Monoclonal Antibodies: a Breakthrough in the Treatment of Migraine
- Calcitonin Gene-Related Peptide (Cgrp) & Migraines
- 401 Pharmacology Update 2021
- PDL)/Non-Preferred Drug List (NPDL
- Eptinezumab-Jjmr Or to Any of the Prescribing Information for VYEPTI
- EXPANDING OUR TX ARSENAL (Dr